This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Odds, F. C.
Right arrow Articles by Van Gerven, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Odds, F. C.
Right arrow Articles by Van Gerven, F.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2000, p. 3180-3183, Vol. 44, No. 11
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Activities of an Intravenous Formulation of Itraconazole in Experimental Disseminated Aspergillus, Candida, and Cryptococcus Infections

Frank C. Odds,1,* Michel Oris,2 Pascal Van Dorsselaer,2 and Frans Van Gerven2

Department of Molecular and Cell Biology, University of Aberdeen, Institute of Medical Sciences, Aberdeen AB25 2ZD, Scotland, United Kingdom,1 and Department of Bacteriology and Mycology, Janssen Research Foundation, B-2340 Beerse, Belgium2

Received 13 March 2000/Returned for modification 11 July 2000/Accepted 8 August 2000

An intravenous (i.v.) formulation of itraconazole was evaluated in disseminated fungal infection models in guinea pigs. In acute disseminated Candida albicans and Aspergillus fumigatus infections, treatment at 5 mg/kg of body weight twice a day (b.i.d.) significantly prolonged survival. In these models and in animals with chronic disseminated cryptococcosis, itraconazole given i.v. at 2.5 and 5 mg/kg b.i.d. greatly reduced the proportions of organs with culture-detectable fungal burdens. The efficacy of i.v. itraconazole in these animal models justifies its further investigation for the treatment of life-threatening mycoses in humans.

* Corresponding author. Mailing address: Department of Molecular and Cell Biology, University of Aberdeen, Institute of Medical Sciences, Foresterhill, Aberdeen AB25 2ZD, Scotland, United Kingdom. Phone: 44 1224 273128. Fax: 44 1224 273144. E-mail: f.odds{at}abdn.ac.uk.

Antimicrobial Agents and Chemotherapy, November 2000, p. 3180-3183, Vol. 44, No. 11
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Kirkpatrick, W. R., Najvar, L. K., Bocanegra, R., Patterson, T. F., Graybill, J. R. (2007). New Guinea Pig Model of Cryptococcal Meningitis. Antimicrob. Agents Chemother. 51: 3011-3013 [Abstract] [Full Text]  
  • MacCallum, D. M., Odds, F. C. (2002). Influence of grapefruit juice on itraconazole plasma levels in mice and guinea pigs. J Antimicrob Chemother 50: 219-224 [Abstract] [Full Text]  
  • Kirkpatrick, W. R., Perea, S., Coco, B. J., Patterson, T. F. (2002). Efficacy of Caspofungin Alone and in Combination with Voriconazole in a Guinea Pig Model of Invasive Aspergillosis. Antimicrob. Agents Chemother. 46: 2564-2568 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»